Education
About Us
Working with TipRanks
Follow Us
Novartis AG (CH:NOVN)
:NOVN
Earnings Data
Report Date
Feb 04, 2026TBA (Confirmed)
Period Ending
2025 (Q4)Consensus EPS Forecast
1.58Last Year’s EPS
1.59Same Quarter Last Year
Based on 12 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Neutral
The earnings call highlighted strong sales growth and significant achievements in key products and pipeline milestones. However, challenges such as generic erosion, Cosentyx's growth issues, and financial adjustments were also notable.Company Guidance
Strong Sales and Core Operating Income Growth
Novartis reported a 7% increase in both sales and core operating income for Q3 2025, with a core margin of 39.3%.
Kisqali's Impressive Growth
Kisqali grew by 68% in Q3, with a 91% increase in the U.S. and 37% growth outside the U.S. The brand is leading in the metastatic breast cancer market.
Pluvicto's Robust Performance
Pluvicto grew 45% in constant currencies, with U.S. sales up 53%. It gained significant market share in the pre-taxane setting.
Leqvio and Scemblix Achievements
Leqvio sales increased by 54%, and Scemblix grew by 95% in constant currencies, showing strong market penetration.
Pipeline Milestones
Novartis achieved FDA approval for Rhapsido, positive Phase III results for Ianalumab, Pluvicto, and Kisqali's 5-year data.
Free Cash Flow and Financial Strength
Free cash flow reached $6.2 billion for Q3, totaling $16 billion for the first nine months, showing a 26% increase from the previous year.
CH:NOVN Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
CH:NOVN Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Oct 28, 2025 | CHF103.16 | CHF98.87 | -4.16% |
Jul 17, 2025 | CHF95.12 | CHF93.34 | -1.87% |
Apr 29, 2025 | CHF93.40 | CHF94.21 | +0.87% |
Jan 31, 2025 | CHF90.56 | CHF92.28 | +1.90% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Novartis AG (CH:NOVN) report earnings?
Novartis AG (CH:NOVN) is schdueled to report earning on Feb 04, 2026, TBA (Confirmed).
What is Novartis AG (CH:NOVN) earnings time?
Novartis AG (CH:NOVN) earnings time is at Feb 04, 2026, TBA (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of Novartis AG stock?
The P/E ratio of Novartis AG is N/A.
What is CH:NOVN EPS forecast?
CH:NOVN EPS forecast for the fiscal quarter 2025 (Q4) is 1.58.